title: In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.
abstract: Surgery and chemotherapy are standard treatments in ovarian cancer, but patients have a high rate of relapse. Dendritic cell (DC)-based vaccines are a new treatment option for elimination of residual tumor disease. We aim to explore the feasibility and immunogenicity of DC vaccines pulsed with autologous irradiated tumor cells from ovarian cancer patients. Monocyte-derived DC were generated and pulsed with autologous tumor-derived bodies, matured and subsequently cocultured with autologous lymphocytes. The ability of DC to activate lymphocytes was evaluated by proliferation and IFN-gamma ELISPOT. Induction of tumor cell apoptosis was optimal at 24 h, and DC pulsing optimal at 4 h. Maturation of DC and proliferation of lymphocytes were achieved in 75% of patients tested. Lymphocyte IFN-gamma production increased in response to tumor antigen-pulsed DC. We show the feasibility of preparing individual DC-based vaccines in ovarian cancer patients and the potential for induction of lymphocyte responses.
authors.affiliation: Department of Immunology, Charles University, 2nd Medical School and Faculty Hospital Motol, V Uvalu 84,150 06 Praha 5, Prague, Czech Republic.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Tobiásová
authors.forename: Dagmar
authors.initials: D
authors.lastname: Pospísilová
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Miller
authors.forename: Ivo
authors.initials: I
authors.lastname: Minárik
authors.forename: Klára
authors.initials: K
authors.lastname: Sochorová
authors.forename: Radek
authors.initials: R
authors.lastname: Spísek
authors.forename: Lukás
authors.initials: L
authors.lastname: Rob
authors.forename: Jirina
authors.initials: J
authors.lastname: Bartůnková
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000276:immunology*; D017209:Apoptosis / Q000502:physiology; D019496:Cancer Vaccines / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D016233:Immunotherapy, Active / Q000379:methods*; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D010587:Phagocytosis / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D007371:Interferon-gamma